Scientists discovered that a drug approach hailed as a breakthrough for fatty liver disease may quadruple cancer risk in aging patients, forcing a complete rethinking of how we treat metabolic liver disease.
Quick Take
- Blocking Caspase-2 enzyme reduces fatty liver disease short-term but increases cancer risk up to four times in older mice
- University of Adelaide research challenges pharmaceutical industry’s push toward Caspase-2 inhibitors as treatment strategy
- Findings highlight critical gap between short-term drug benefits and long-term safety outcomes in aging populations
- Study suggests lifestyle changes and alternative therapies may be safer than enzyme-blocking drugs for liver disease management
The Cure That Backfires
Researchers at the University of Adelaide published findings in Science Advances revealing a counterintuitive truth: blocking Caspase-2, an enzyme previously believed protective against fatty liver disease, paradoxically increases chronic liver damage and cancer risk over time. Mice lacking functional Caspase-2 developed liver tumors at rates four times higher than normal mice, with characteristics matching human hepatocellular carcinoma. The discovery directly contradicts prevailing assumptions in pharmaceutical development and forces immediate reconsideration of multiple drugs in development pipelines.
Why This Matters Now
Fatty liver disease affects approximately one in four American adults, representing a massive at-risk population desperately seeking effective treatments. Globally, liver cancer caused nearly 760,000 deaths in 2022 alone, making it the sixth most common cancer. The pharmaceutical industry invested heavily in Caspase-2 inhibitors based on earlier research suggesting enzyme blocking could interrupt disease progression. This new research shatters that assumption and forces companies to halt or redirect development programs currently in clinical trial phases.
Dr. Loretta Dorstyn, lead researcher, emphasized the distinction between immediate and delayed effects: “While inhibiting this enzyme can be protective in young animals or may help prevent fatty liver disease in the short term, our study shows that its long-term loss is clearly detrimental.” Her team identified the mechanism: Caspase-2 normally removes damaged liver cells, preventing them from becoming cancerous. Block the enzyme, and damaged cells survive and accumulate mutations over decades.
The Aging Population Problem
Elderly patients face the highest risk from this approach. As people age, the liver’s ability to manage metabolic stress declines naturally. Removing Caspase-2’s protective function compounds this vulnerability, creating what researchers describe as a perfect environment for cancer development. The four-fold increase in tumor rates occurred specifically in older mice, suggesting that younger patients might tolerate short-term treatment without immediate consequence—but long-term safety remains unknown.
Professor Sharad Kumar, senior author, warned of broader implications: “Our data shows that this approach could have serious unintended consequences later in life, increasing susceptibility to chronic liver inflammation, fibrosis and cancer.” This statement represents a direct challenge to the entire therapeutic strategy that pharmaceutical companies have pursued for years.
What Caused This Wrong Turn
The pharmaceutical industry made a logical but incomplete assumption: if Caspase-2 helps prevent fatty liver disease, inhibiting it should amplify protection. This reasoning ignored the enzyme’s dual role across the lifespan. Early research focused on young animals where short-term benefits appeared obvious. Nobody studied long-term outcomes in aging populations until now, revealing the classic trap of extrapolating short-term drug effects into lifelong safety profiles.
Complementary research from MIT in 2025 identified another piece of the puzzle: high-fat diets cause liver cells to revert to immature, stem-cell-like states. This cellular adaptation prioritizes survival under stress but increases long-term cancer susceptibility. Combined with Caspase-2 loss, this creates a compounding effect where damaged cells cannot be eliminated and continue dividing.
The Path Forward
Regulatory agencies now face critical decisions about existing Caspase-2 inhibitor programs. Clinical trials may be halted or redesigned with longer safety monitoring periods. Pharmaceutical companies must either pivot to alternative mechanisms or accept that this therapeutic approach carries unacceptable long-term risks. The research suggests future strategies should target underlying metabolic dysfunction rather than broadly inhibiting cellular protective mechanisms.
A promising fatty liver treatment may raise cancer risk: https://t.co/CvWjzMZT9R
— Ken Gusler (@kgusler) March 23, 2026
For patients with fatty liver disease, the evidence increasingly supports lifestyle interventions as the safest approach. Dietary modification, particularly reducing high-fat intake, addresses the root metabolic problem without introducing long-term cancer risk. While less profitable than pharmaceutical solutions, this strategy aligns with biological reality: the liver responds to what we feed it, and changing diet changes the liver’s behavior at the cellular level.
Sources:
A Promising Fatty Liver Treatment May Raise Cancer Risk
University of Adelaide Study on Caspase-2 and Liver Cancer Risk
Cedars-Sinai Researchers Target Liver Disease and Cancer
MIT Study: High-Fat Diets Make Liver Cells More Likely to Become Cancerous
Rutgers University: How Simple Dietary Change May Slow Liver Cancer Risk
